<DOC>
	<DOCNO>NCT01463150</DOCNO>
	<brief_summary>The use dual antiplatelet therapy consider standard care patient post percutaneous coronary intervention ( PCI ) stenting . However , significant proportion patient consider clopidogrel resistant resistance show accompanied future adverse event . The aim study define consecutive patient acute coronary syndrome ( ACS ) undergo PCI , age &gt; 75years and/or weight &lt; 60 Kg high on-clopidogrel platelet reactivity ( Platelet Reactivity Units-PRU≥235 ) estimate 24 hour post PCI VerifyNow assay . Those patient randomize informed concent 1:1 fashion prasugrel 5 mg clopidogrel 150mg daily . Platelet reactivity assess day 15 treatment crossover perform . At day 30 platelet reactivity determine well .</brief_summary>
	<brief_title>Prasugrel 5mg Versus High Dose Clopidogrel Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing &lt; 60 kg Post Percutaneous Coronary Intervention ( PCI )</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>1 . Age ≥18 year old 2 . Patients PCI stenting 24 hour prior randomization , meet follow criterion : Acute coronary syndrome ( unstable angina myocardial infarction ) TIMI risk score &gt; 2 3 . Platelet reactivity PRU ≥235 24 hour postPCI 4 . Age≥75 year and/or weight &lt; 60 Kg 4 . Informed consent obtain write A history bleed diathesis Chronic oral anticoagulation treatment Contraindications antiplatelet therapy Known platelet function disorder PCI coronary artery bypass surgery &lt; 3 month Unsuccessful PCI ( residual stenosis &gt; 30 % flow &lt; Thrombolysis myocardial infarction flow 3 ) Planned stag PCI next 30 day Hemodynamic instability hemodialysis Creatinine clearance &lt; 25 ml/min inability give inform consent High likelihood unavailable Day 30 History gastrointestinal bleeding , genitourinary bleeding site abnormal bleeding within previous 6 month . Other bleed diathesis , consider investigator high risk bleed longterm antiplatelet therapy . Any previous history ischemic stroke , transient ischemic attack , intracranial hemorrhage disease ( neoplasm , arteriovenous malformation , aneurysm ) . Thrombocytopenia ( &lt; 100.000 / μL ) randomization Anaemia ( Hct &lt; 30 % ) randomization Polycythaemia ( Hct &gt; 52 % ) randomization Periprocedural IIb/IIIa inhibitor administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Platelet reactivity</keyword>
	<keyword>Clopidogrel</keyword>
	<keyword>Prasugrel</keyword>
</DOC>